Metal Fragment in Tablet Prompts Recall

A pharmacist’s report of a metal fragment embedded in a tablet has prompted a recall for 222 600 bottles of lisinopril, according to the November 27, 2024, US Food and Drug Administration (FDA) Enforcement Report. 

The recall affects lisinopril tablets, 10 mg, in 90-count bottles, from lot 241103 (Exp. 5/31/26). The tablets were manufactured for Camber Pharmaceuticals Inc., Piscataway, New Jersey,  packaged by Legacy Pharmaceutical Packaging, Earth City, Missouri, and distributed by Walmart, Bentonville, Arkansas, throughout the United States.

Evaric Pharmaceuticals Inc. voluntarily initiated the recall on November 15, 2024. On November 20, 2024, the FDA designated the recall Class II. Drugs affected by Class II recalls may cause temporary or medically reversible adverse health consequences if used. While remote, a possibility of serious harm also exists.

Lisinopril is a prescription angiotensin-converting enzyme (ACE) inhibitor used to treat patients with high blood pressure, heart failure, and acute myocardial infarction.